Kidney RSS News Feeds

Nephrology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Renneville A et al. - In a study to determine whether WT1 mutations are a predictor of poor outcome in pts with acute myeloid leukemia (AML), it was reported that WT1 mutations represent an adverse prognostic factor in young adults with AML. Prospective trials should confirm the clinical relevance of WT1 mutations in relation to other prognostic factors in pts with AML.

Methods

Results


Today in Hematology/Oncology...keeping you current

Upfront, randomized, phase II trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma
Cancer, 11/03/09

A Randomized Controlled Study of Weekly and Biweekly Dosing of Epoetin Alfa in CKD Patients With Anemia
Clinical Journal of the American Society of Nephrology, 11/05/09

Incidence of brain metastases in renal cell carcinoma treated with sorafenib
Annals of Oncology, 10/29/09

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address